Evidence mapPaperPMID 41746975Full record

ArticlePloS one2026

Effects of tacrolimus treatment on the gut microbiota and metabolites in liver transplant recipients.

Guohui Wang, Lu Liu, Hanshu Zhang, Panpan Mao, Saijuan Lu, Xiaofang Zhang, Xingde Li, Cangsang Song

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Guohui WangDepartment of Pharmacy, The First People's Hospital of Kunming City and Calmette Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.ORCID https://orcid.org/0009-0009-3156-9949
Lu LiuDepartment of Pharmacy, The First People's Hospital of Kunming City and Calmette Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Hanshu ZhangDepartment of Pharmacy, The First People's Hospital of Kunming City and Calmette Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Panpan MaoDepartment of Pharmacy, The First People's Hospital of Kunming City and Calmette Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Saijuan LuDepartment of Pharmacy, The First People's Hospital of Kunming City and Calmette Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Xiaofang ZhangDepartment of Pharmacy, The First People's Hospital of Kunming City and Calmette Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Xingde LiDepartment of Pharmacy, The First People's Hospital of Kunming City and Calmette Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Cangsang SongDepartment of Pharmacy, The First People's Hospital of Kunming City and Calmette Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLiver transplantation (LT) is an effective treatment for patients with end-stage liver disease. In recent years, more and more evidence has supported the association between gut microbiota dysbiosis and the pathogenesis and progression of liver diseases.

methodsThe study included 36 patients who received tacrolimus treatment after liver transplantation. Patients were stratified into subgroups according to three key variables: tacrolimus treatment duration, whole-blood tacrolimus concentration, and tacrolimus concentration-to-dose (C/D) ratio. Fecal samples and whole-blood specimens were collected from all participants. The Illumina HiSeq X platform was used to detect the gut metagenome, analyzing the composition and characteristics of the gut microbiota. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology was employed to detect metabolites of the gut microbiota, revealing their metabolic profiles.

resultsAs the duration of tacrolimus use increased, the diversity of the gut microbiota also increased, and the abundance of Escherichia coli_D and Bacteroides stercoris rose. Additionally, the abundance of Brunovirus and Uetakevirus tended to decrease. The abundance of gene functions related to chemical carcinogenesis and bacterial invasion of epithelial cells significantly decreased. In the gut microbiota metabolites, 16 substances like Astragaloside A and Acetyl-L-carnitine significantly increased, while 108 substances like Capsaicin and TLK significantly decreased. Within a certain range, as the concentration of tacrolimus in whole blood increased, the diversity of the gut microbiota increased. The abundance of Phocaeicola and Klebsiella increased, and the abundance of Peduovirus among viruses also rose. However, excessively high concentrations may lead to a decrease in the diversity of the gut microbiota and a decrease in the abundance of Phocaeicola. With respect to the C/D ratio, increased ratios were linked to significantly higher levels of 57 fecal metabolites (e.g., PC 34:2, 5-Methyl-2'-deoxycytidine), whereas 13 metabolites (e.g., FAHFA 2:0/16:0) showed substantial declines.

conclusionsTacrolimus treatment is associated with distinct alterations in gut microbiota and metabolites among LT recipients. These findings provide a preliminary framework for future investigations aimed at optimizing immunosuppressive regimens, although their clinical translational potential requires validation in larger-scale, prospective cohort studies.

Indexed as

Gastrointestinal MicrobiomeImmunosuppressive AgentsLiver TransplantationTacrolimusAdultFecesFemaleHumansMaleMiddle AgedImmunosuppressive AgentsTacrolimus

Identifiers

PMID41746975
PMCPMC12944773

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.